The use of interleukin-2 (IL-2), a T-cell growth factor, has enabled large-scale in vitro expansion of TILs and demonstrated increased lethality against tumor cells in conditions such as melanoma, HCC, lung carcinoma, ovarian cancer, and other solid tumors [53]. Here, IL2 is linked to hepatocellular carcinoma.